Process and Product Development Subcommittee


The Process and Product Development Subcommittee strives to:

  • Establish and communicate best practices in Process and Product Development (PPD) as it relates to therapeutic cell based products.
  • Assess emerging cell processing technologies and forecast their impact on the commercialization process.

Click here to view the full charter.

Projects and Objectives

  • Educational Webinars: Process Development is a discipline learned on the job and there are few texts that cover many of the best practices used in the field—and fewer available that discuss Cell Therapy-specific requirements. The Process and Product Development Subcommittee develops educational webinars to cover best practices in Cell Therapy Process Development. Click here to view upcoming webinars.
  • White papers: White papers are an important vehicle for the PPD to educate and influence the field. White papers will be published in peer-reviewed journals to increase credibility and visibility of the PPD and ISCT. Click here to view the published PPD white papers.
  • ISCT Annual Meeting: The PPD will be actively involved in the organization of the ISCT Annual Meeting. At least one session in the Strategies for Commercialization Track will be organized by this committee.




Committee Chair


Dominic Clarke, PhD
Winston Salem,NC, United States

John Fink, MBA
Pall Corporation
Boston, MA, United States


Committee Members


Alireza Abazari, PhD
BioLife Solutions
Bothell, WA, United States

Eytan Abraham, PhD
Walkersville, MA, United States

Sasha Aleksic, MSc
Irvine Scientific
Irvine, CA, United States

Julie Allickson, PhD, MSc, MT(ASCP)
Wake Forest Institute for Regenerative Medicine
Winston-Salem, NC, United States

Hyalker Amaral, MBA
Terumo BCT
Denver, CO, United States

Behnam Ahmadian Baghbaderani, PhD
Lonza Walkersville
Walkersville, MD, United States

Harvey Brandwein, PhD
Cook Regentec
Port Washington, NY, United States

Christopher Bravery, PhD
Advanced Biologicals Ltd.
London, United Kingdom


Scott Burger, MD
Advanced Cell & Gene Therapy
Chapel Hill, NC, United States

Shannon Eaker, PhD
GE Healthcare 
Knoxville, TN, United States
David Fiorentini, MSc
Biological Industries
Beit-Haemek, Israel
Maya Fuerstenau-Sharp, PhD
Sartorius-Stedim Biotech
Gottingen, Germany
Clive Glover, PhD
Pall Life Sciences
Portsmouth, United Kingdom

Heidi Hagen, MS, MBA
Seattle, WA, United States


Robert Jones
London, United Kingdom

Ohad Karnieli, PhD, MBA
Atvio Biotech
Haifa, Israel
Julie Kerby, PhD
Cell & Gene Therapy Catapult
London, United Kingdom
Mark Leonard
San Francisco, CA, United States
Kara Levine, PhD
Bedford, MA, United States
Yonatan Lipsitz, PhD
Rubius Therapeutics 
Boston, MA, United States
Katy McGirr, PhD
Bedford,MA, United States
Michael Mendicino, PhD
Hybrid Concepts International, LLC
Grand Island, NY, United States
Grace O'Connell, PhD
UC Berkeley
Berkely, CA, United States
Steve Oh, PhD
Jean-Sébastien Parisse
Aseptic Technologies
Gembloux, Belgium
Ulrike Rehn, PhD
Thermo Fisher Scientific
Buffalo, NY, United States
Alaina Schlinker, PhD
Lake Zurich, IL, United States

Michael Scott, PhD
BlueRock Therapeutics
Toronto, ON, Canada

David Smith, PhD
Hitachi Chemical Advanced Therapeutic Solutions (HCATS)
Allendale, NJ, United States




Jean-Sébastien Parisse
Asceptic Technologies
Isnes, Belgium

© 2019 ISCT. All rights reserved. 
ISCT, and the ISCT logo are registered trademarks of the International Society for Cellular Therapy.
The BEACON and lighthouse logo is a service mark of the International Society for Cellular Therapy.

ISCT Privacy Policy